Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 143 articles:
HTML format
Text format



Single Articles


    January 2019
  1. RODRIGUEZ-SANCHEZ L, Fernandez-Navarro P, Lopez-Abente G, Nunez O, et al
    Different spatial pattern of municipal prostate cancer mortality in younger men in Spain.
    PLoS One. 2019;14:e0210980.
    PubMed     Text format     Abstract available


  2. GOUPY F, Supiot S, Pasquier D, Latorzeff I, et al
    Intensity-modulated radiotherapy for prostate cancer with seminal vesicle involvement (T3b): A multicentric retrospective analysis.
    PLoS One. 2019;14:e0210514.
    PubMed     Text format     Abstract available


  3. JEGERLEHNER S, Chiolero A, Aujesky D, Rodondi N, et al
    Recent incidence and surgery trends for prostate cancer: Towards an attenuation of overdiagnosis and overtreatment?
    PLoS One. 2019;14:e0210434.
    PubMed     Text format     Abstract available


  4. KARLSSON A, Jauhiainen A, Gulati R, Eklund M, et al
    A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry data.
    PLoS One. 2019;14:e0211918.
    PubMed     Text format     Abstract available


  5. LAI CC, Huang PH, Wang FN, Shen SH, et al
    Histogram analysis of prostate cancer on dynamic contrast-enhanced magnetic resonance imaging: A preliminary study emphasizing on zonal difference.
    PLoS One. 2019;14:e0212092.
    PubMed     Text format     Abstract available


  6. ANTICO M, Prinsen P, Cellini F, Fracassi A, et al
    Real-time adaptive planning method for radiotherapy treatment delivery for prostate cancer patients, based on a library of plans accounting for possible anatomy configuration changes.
    PLoS One. 2019;14:e0213002.
    PubMed     Text format     Abstract available


  7. TAKAKUSAGI Y, Kawamura H, Okamoto M, Kaminuma T, et al
    Long-term outcome of hypofractionated intensity-modulated radiotherapy using TomoTherapy for localized prostate cancer: A retrospective study.
    PLoS One. 2019;14:e0211370.
    PubMed     Text format     Abstract available


  8. KANNAN A, Kirkman M, Ruseckaite R, Evans SM, et al
    Prostate cancer awareness, case-finding, and early diagnosis: Interviews with undiagnosed men in Australia.
    PLoS One. 2019;14:e0211539.
    PubMed     Text format     Abstract available


    January 2018
  9. YANG F, Yu N, Wang H, Zhang C, et al
    Downregulated expression of hepatoma-derived growth factor inhibits migration and invasion of prostate cancer cells by suppressing epithelial-mesenchymal transition and MMP2, MMP9.
    PLoS One. 2018;13:e0190725.
    PubMed     Text format     Abstract available


  10. SRIVASTAVA P, Sarma A, Chaturvedi CM
    Targeting DNA repair with PNKP inhibition sensitizes radioresistant prostate cancer cells to high LET radiation.
    PLoS One. 2018;13:e0190516.
    PubMed     Text format     Abstract available


  11. BYUN SJ, Kim YS, Ahn H, Kim CS, et al
    Image-guided, whole-pelvic, intensity-modulated radiotherapy for biochemical recurrence following radical prostatectomy in high-risk prostate cancer patients.
    PLoS One. 2018;13:e0190479.
    PubMed     Text format     Abstract available


  12. BARAKAT DJ, Suresh R, Barberi T, Pienta KJ, et al
    Absence of myeloid Klf4 reduces prostate cancer growth with pro-atherosclerotic activation of tumor myeloid cells and infiltration of CD8 T cells.
    PLoS One. 2018;13:e0191188.
    PubMed     Text format     Abstract available


  13. HAYES AR, Brungs D, Pavlakis N
    Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: A systematic review and meta-analysis.
    PLoS One. 2018;13:e0191455.
    PubMed     Text format     Abstract available


  14. KORONOWICZ AA, Drozdowska M, Wielgos B, Piasna-Slupecka E, et al
    The effect of "NutramilTM Complex," food for special medical purpose, on breast and prostate carcinoma cells.
    PLoS One. 2018;13:e0192860.
    PubMed     Text format     Abstract available


  15. GILLEBERT Q, Huchet V, Rousseau C, Cochet A, et al
    18F-fluorocholine PET/CT in patients with occult biochemical recurrence of prostate cancer: Detection rate, impact on management and adequacy of impact. A prospective multicentre study.
    PLoS One. 2018;13:e0191487.
    PubMed     Text format     Abstract available


  16. JAYARAMAN A, Kumar P, Marin S, de Atauri P, et al
    Untargeted metabolomics reveals distinct metabolic reprogramming in endothelial cells co-cultured with CSC and non-CSC prostate cancer cell subpopulations.
    PLoS One. 2018;13:e0192175.
    PubMed     Text format     Abstract available


  17. EGGER S, Hughes S, Smith DP, Chambers S, et al
    Factors associated with the use of complementary and alternative medicines for prostate cancer by long-term survivors.
    PLoS One. 2018;13:e0193686.
    PubMed     Text format     Abstract available


  18. SHIN H, Park YH, Kim YG, Lee JY, et al
    Aqueous two-phase system to isolate extracellular vesicles from urine for prostate cancer diagnosis.
    PLoS One. 2018;13:e0194818.
    PubMed     Text format     Abstract available


  19. RUSSELL B, Garmo H, Beckmann K, Stattin P, et al
    A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0.
    PLoS One. 2018;13:e0195690.
    PubMed     Text format     Abstract available


  20. FRYZEK JP, Reichert H, Summers N, Townes L, et al
    Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen.
    PLoS One. 2018;13:e0195790.
    PubMed     Text format     Abstract available


  21. GOINEAU A, Campion L, d'Aillieres B, Vie B, et al
    Comprehensive Geriatric Assessment and quality of life after localized prostate cancer radiotherapy in elderly patients.
    PLoS One. 2018;13:e0194173.
    PubMed     Text format     Abstract available


  22. CAMPBELL DH, Lund ME, Nocon AL, Cozzi PJ, et al
    Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer.
    PLoS One. 2018;13:e0196017.
    PubMed     Text format     Abstract available


  23. WALSH DMJ, Groarke AM, Morrison TG, Durkan G, et al
    Measuring a new facet of post traumatic growth: Development of a scale of physical post traumatic growth in men with prostate cancer.
    PLoS One. 2018;13:e0195992.
    PubMed     Text format     Abstract available


  24. CHEUNG S, Hamuro Y, Mahlich J, Nakayama M, et al
    Treatment pathways of Japanese prostate cancer patients - A retrospective transition analysis with administrative data.
    PLoS One. 2018;13:e0195789.
    PubMed     Text format     Abstract available


  25. SCHWEIZER MT, Haugk K, McKiernan JS, Gulati R, et al
    A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.
    PLoS One. 2018;13:e0198389.
    PubMed     Text format     Abstract available


  26. MARU S, Uchino H, Osawa T, Chiba S, et al
    Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy.
    PLoS One. 2018;13:e0197252.
    PubMed     Text format     Abstract available


  27. SMITH DP, Calopedos R, Bang A, Yu XQ, et al
    Increased risk of suicide in New South Wales men with prostate cancer: Analysis of linked population-wide data.
    PLoS One. 2018;13:e0198679.
    PubMed     Text format     Abstract available


  28. PARK JW, Koh DH, Jang WS, Lee JY, et al
    Age-adjusted Charlson Comorbidity Index as a prognostic factor for radical prostatectomy outcomes of very high-risk prostate cancer patients.
    PLoS One. 2018;13:e0199365.
    PubMed     Text format     Abstract available


  29. KARUNASINGHE N, Ambs S, Wang A, Tang W, et al
    Influence of lifestyle and genetic variants in the aldo-keto reductase 1C3 rs12529 polymorphism in high-risk prostate cancer detection variability assessed between US and New Zealand cohorts.
    PLoS One. 2018;13:e0199122.
    PubMed     Text format     Abstract available


  30. EBBING J, Jaderling F, Collins JW, Akre O, et al
    Comparison of 3D printed prostate models with standard radiological information to aid understanding of the precise location of prostate cancer: A construct validation study.
    PLoS One. 2018;13:e0199477.
    PubMed     Text format     Abstract available


  31. LEE H, Hwang SI, Lee HJ, Byun SS, et al
    Diagnostic performance of diffusion-weighted imaging for prostate cancer: Peripheral zone versus transition zone.
    PLoS One. 2018;13:e0199636.
    PubMed     Text format     Abstract available


  32. WALSH TJ, Shores MM, Krakauer CA, Forsberg CW, et al
    Testosterone treatment and the risk of aggressive prostate cancer in men with low testosterone levels.
    PLoS One. 2018;13:e0199194.
    PubMed     Text format     Abstract available


  33. FERRARINI A, Forcato C, Buson G, Tononi P, et al
    A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products.
    PLoS One. 2018;13:e0193689.
    PubMed     Text format     Abstract available


  34. BOURKE L, Turner R, Greasley R, Sutton E, et al
    A multi-centre investigation of delivering national guidelines on exercise training for men with advanced prostate cancer undergoing androgen deprivation therapy in the UK NHS.
    PLoS One. 2018;13:e0197606.
    PubMed     Text format     Abstract available


  35. DANKERT JT, Wiesehofer M, Czyrnik ED, Singer BB, et al
    The deregulation of miR-17/CCND1 axis during neuroendocrine transdifferentiation of LNCaP prostate cancer cells.
    PLoS One. 2018;13:e0200472.
    PubMed     Text format     Abstract available


  36. KOITSALU M, Eklund M, Adolfsson J, Sprangers MAG, et al
    Predictors of participation in risk-based prostate cancer screening.
    PLoS One. 2018;13:e0200409.
    PubMed     Text format     Abstract available


  37. PRITCHARD AL, Johansson PA, Nathan V, Howlie M, et al
    Germline mutations in candidate predisposition genes in individuals with cutaneous melanoma and at least two independent additional primary cancers.
    PLoS One. 2018;13:e0194098.
    PubMed     Text format     Abstract available


  38. NAIR-SHALLIKER V, Egger S, Chrzanowska A, Mason R, et al
    Associations between sun sensitive pigmentary genes and serum prostate specific antigen levels.
    PLoS One. 2018;13:e0193893.
    PubMed     Text format     Abstract available


  39. SCHAAKE W, van der Schaaf A, van Dijk LV, van den Bergh ACM, et al
    Development of a prediction model for late urinary incontinence, hematuria, pain and voiding frequency among irradiated prostate cancer patients.
    PLoS One. 2018;13:e0197757.
    PubMed     Text format     Abstract available


  40. TENTORI K, Pighin S, Divan C, Crupi V, et al
    Mind the gap: Physicians' assessment of patients' importance weights in localized prostate cancer.
    PLoS One. 2018;13:e0200780.
    PubMed     Text format     Abstract available


  41. BIALKOWSKA K, Marciniak W, Muszynska M, Baszuk P, et al
    Association of zinc level and polymorphism in MMP-7 gene with prostate cancer in Polish population.
    PLoS One. 2018;13:e0201065.
    PubMed     Text format     Abstract available


  42. HILLEBRAND AC, Pizzolato LS, Neto BS, Branchini G, et al
    Androgen receptor isoforms expression in benign prostatic hyperplasia and primary prostate cancer.
    PLoS One. 2018;13:e0200613.
    PubMed     Text format     Abstract available


  43. JANSEN RJ, Alexander BH, Hayes RB, Miller AB, et al
    A mathematical model of case-ascertainment bias: Applied to case-control studies nested within a randomized screening trial.
    PLoS One. 2018;13:e0194608.
    PubMed     Text format     Abstract available


  44. PUNNEN S, Nahar B, Soodana-Prakash N, Koru-Sengul T, et al
    Optimizing patient's selection for prostate biopsy: A single institution experience with multi-parametric MRI and the 4Kscore test for the detection of aggressive prostate cancer.
    PLoS One. 2018;13:e0201384.
    PubMed     Text format     Abstract available


  45. KOIKE Y, Sumida I, Mizuno H, Shiomi H, et al
    Dosimetric impact of intra-fraction prostate motion under a tumour-tracking system in hypofractionated robotic radiosurgery.
    PLoS One. 2018;13:e0195296.
    PubMed     Text format     Abstract available


  46. SCHWEIZER MT, Haugk K, McKiernan JS, Gulati R, et al
    Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.
    PLoS One. 2018;13:e0202709.
    PubMed     Text format     Abstract available


  47. YE Y, Li SL, Wang SY
    Construction and analysis of mRNA, miRNA, lncRNA, and TF regulatory networks reveal the key genes associated with prostate cancer.
    PLoS One. 2018;13:e0198055.
    PubMed     Text format     Abstract available


  48. BRIDGES D, Kawamura H, Kanai T
    Probabilistic dose distribution from interfractional motion in carbon ion radiation therapy for prostate cancer shows rectum sparing with moderate target coverage degradation.
    PLoS One. 2018;13:e0203289.
    PubMed     Text format     Abstract available


  49. PENZIAS G, Singanamalli A, Elliott R, Gollamudi J, et al
    Identifying the morphologic basis for radiomic features in distinguishing different Gleason grades of prostate cancer on MRI: Preliminary findings.
    PLoS One. 2018;13:e0200730.
    PubMed     Text format     Abstract available


  50. KIM JJ, Kim T, Lee H, Byun SS, et al
    Prediction of unilateral prostate cancer by the combination of transrectal ultrasonography-guided prostate biopsy and multi-parametric magnetic resonance imaging: A real-life experience.
    PLoS One. 2018;13:e0202872.
    PubMed     Text format     Abstract available


  51. GUO Y, Wang L, Hu J, Feng D, et al
    Diagnostic performance of choline PET/CT for the detection of bone metastasis in prostate cancer: A systematic review and meta-analysis.
    PLoS One. 2018;13:e0203400.
    PubMed     Text format     Abstract available


  52. LIN HW, Lin LF, Chen HC, Liou TH, et al
    Chronic obstructive pulmonary disease with short-acting inhaled pharmacotherapy increases the risk of prostate cancer: A two-stage database approach.
    PLoS One. 2018;13:e0203377.
    PubMed     Text format     Abstract available


  53. HASAN D, Gamen E, Abu Tarboush N, Ismail Y, et al
    PKM2 and HIF-1alpha regulation in prostate cancer cell lines.
    PLoS One. 2018;13:e0203745.
    PubMed     Text format     Abstract available


  54. MOSES-FYNN E, Tang W, Beyene D, Apprey V, et al
    Correlating blood-based DNA methylation markers and prostate cancer risk in African-American men.
    PLoS One. 2018;13:e0203322.
    PubMed     Text format     Abstract available


  55. CHOI YJ, Lee DH, Han KD, Yoon H, et al
    Is nonalcoholic fatty liver disease associated with the development of prostate cancer? A nationwide study with 10,516,985 Korean men.
    PLoS One. 2018;13:e0201308.
    PubMed     Text format     Abstract available


  56. MILOSAVLJEVIC V, Haddad Y, Merlos Rodrigo MA, Moulick A, et al
    Correction: The Zinc-Schiff Base-Novicidin Complex as a Potential Prostate Cancer Therapy.
    PLoS One. 2018;13:e0204441.
    PubMed     Text format     Abstract available


  57. LEIGHTON X, Bera A, Eidelman O, Bubendorf L, et al
    Tissue microarray analysis delineate potential prognostic role of Annexin A7 in prostate cancer progression.
    PLoS One. 2018;13:e0205837.
    PubMed     Text format     Abstract available


  58. WU X, Zhang K, Chen Y, Wang R, et al
    Theoretical and experimental study of dual-fiber laser ablation for prostate cancer.
    PLoS One. 2018;13:e0206065.
    PubMed     Text format     Abstract available


  59. BABALYAN K, Sultanov R, Generozov E, Sharova E, et al
    LogLoss-BERAF: An ensemble-based machine learning model for constructing highly accurate diagnostic sets of methylation sites accounting for heterogeneity in prostate cancer.
    PLoS One. 2018;13:e0204371.
    PubMed     Text format     Abstract available


  60. ZHANG S, Zheng C, Yao S, Wang Z, et al
    Proteomic analysis of human prostate cancer PC-3M-1E8 cells and PC-3M-2B4 cells of same origin but with different metastatic potential.
    PLoS One. 2018;13:e0206139.
    PubMed     Text format     Abstract available


  61. ZHANG X, Lin Y, Xie X, Shen M, et al
    Is acne in adolescence associated with prostate cancer risk? Evidence from a meta-analysis.
    PLoS One. 2018;13:e0206249.
    PubMed     Text format     Abstract available


  62. VARNAVA M, Sumida I, Mizuno H, Shiomi H, et al
    A new plan quality objective function for determining optimal collimator combinations in prostate cancer treatment with stereotactic body radiation therapy using CyberKnife.
    PLoS One. 2018;13:e0208086.
    PubMed     Text format     Abstract available


  63. CHIU TD, Arai TJ, Campbell Iii J, Jiang SB, et al
    MR-CBCT image-guided system for radiotherapy of orthotopic rat prostate tumors.
    PLoS One. 2018;13:e0198065.
    PubMed     Text format     Abstract available


  64. GROCHTDREIS T, Konig HH, Dobruschkin A, von Amsberg G, et al
    Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review.
    PLoS One. 2018;13:e0208063.
    PubMed     Text format     Abstract available


  65. HUANG MH, Blackwood J, Godoshian M, Pfalzer L, et al
    Factors associated with self-reported falls, balance or walking difficulty in older survivors of breast, colorectal, lung, or prostate cancer: Results from Surveillance, Epidemiology, and End Results-Medicare Health Outcomes Survey linkage.
    PLoS One. 2018;13:e0208573.
    PubMed     Text format     Abstract available


  66. TINZL M, Chen B, Chen SY, Semenas J, et al
    Correction: Interaction between c-jun and Androgen Receptor Determines the Outcome of Taxane Therapy in Castration Resistant Prostate Cancer.
    PLoS One. 2018;13:e0209544.
    PubMed     Text format     Abstract available


  67. PARK JW, Lee JH, Cho HJ, Ha YJ, et al
    Influence of androgen deprivation therapy on serum urate levels in patients with prostate cancer: A retrospective observational study.
    PLoS One. 2018;13:e0209049.
    PubMed     Text format     Abstract available


  68. CHUNG DY, Goh HJ, Koh DH, Kim MS, et al
    Clinical significance of multiparametric MRI and PSA density as predictors of residual tumor (pT0) following radical prostatectomy for T1a-T1b (incidental) prostate cancer.
    PLoS One. 2018;13:e0210037.
    PubMed     Text format     Abstract available


  69. FONSECA-ALVES CE, Kobayashi PE, Rivera Calderon LG, Felisbino SL, et al
    Immunohistochemical panel to characterize canine prostate carcinomas according to aberrant p63 expression.
    PLoS One. 2018;13:e0199173.
    PubMed     Text format     Abstract available


  70. GUPTA S, Silveira DA, Mombach JCM
    Modeling the role of microRNA-449a in the regulation of the G2/M cell cycle checkpoint in prostate LNCaP cells under ionizing radiation.
    PLoS One. 2018;13:e0200768.
    PubMed     Text format     Abstract available


  71. ARAS O, Pearce G, Watkins AJ, Nurili F, et al
    An in-vivo pilot study into the effects of FDG-mNP in cancer in mice.
    PLoS One. 2018;13:e0202482.
    PubMed     Text format     Abstract available


  72. GOMEZ-ACEBO I, Dierssen-Sotos T, Palazuelos C, Fernandez-Navarro P, et al
    Pigmentation phototype and prostate and breast cancer in a select Spanish population-A Mendelian randomization analysis in the MCC-Spain study.
    PLoS One. 2018;13:e0201750.
    PubMed     Text format     Abstract available


    January 2017
  73. SEO Y, Ryu K, Park J, Jeon DK, et al
    Inhibition of ANO1 by luteolin and its cytotoxicity in human prostate cancer PC-3 cells.
    PLoS One. 2017;12:e0174935.
    PubMed     Text format     Abstract available


  74. LE B, Powers GL, Tam YT, Schumacher N, et al
    Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer.
    PLoS One. 2017;12:e0174658.
    PubMed     Text format     Abstract available


  75. LYNCH SM, Mitra N, Ross M, Newcomb C, et al
    A Neighborhood-Wide Association Study (NWAS): Example of prostate cancer aggressiveness.
    PLoS One. 2017;12:e0174548.
    PubMed     Text format     Abstract available


  76. FAN CY, Huang WY, Lin CS, Su YF, et al
    Risk of second primary malignancies among patients with prostate cancer: A population-based cohort study.
    PLoS One. 2017;12:e0175217.
    PubMed     Text format     Abstract available



  77. Correction: Development and External Validation of the Korean Prostate Cancer Risk Calculator for High-Grade Prostate Cancer: Comparison with Two Western Risk Calculators in an Asian Cohort.
    PLoS One. 2017;12:e0175606.
    PubMed     Text format     Abstract available


  78. PANG KH, Rosario DJ, Morgan SL, Catto JW, et al
    Evaluation of a short RNA within Prostate Cancer Gene 3 in the predictive role for future cancer using non-malignant prostate biopsies.
    PLoS One. 2017;12:e0175070.
    PubMed     Text format     Abstract available


  79. ROHENA-RIVERA K, Sanchez-Vazquez MM, Aponte-Colon DA, Forestier-Roman IS, et al
    IL-15 regulates migration, invasion, angiogenesis and genes associated with lipid metabolism and inflammation in prostate cancer.
    PLoS One. 2017;12:e0172786.
    PubMed     Text format     Abstract available


  80. MARTINEZ-MARIN D, Jarvis C, Nelius T, de Riese W, et al
    PEDF increases the tumoricidal activity of macrophages towards prostate cancer cells in vitro.
    PLoS One. 2017;12:e0174968.
    PubMed     Text format     Abstract available


  81. ONUKWUGHA E, Kwok Y, Ciezki JP, Yong C, et al
    Skeletal-related events and mortality among men diagnosed with advanced prostate cancer: The impact of alternative measures of radiation to the bone.
    PLoS One. 2017;12:e0175956.
    PubMed     Text format     Abstract available


  82. AL AAMERI RFH, Sheth S, Alanisi EMA, Borse V, et al
    Tonic suppression of PCAT29 by the IL-6 signaling pathway in prostate cancer: Reversal by resveratrol.
    PLoS One. 2017;12:e0177198.
    PubMed     Text format     Abstract available


  83. OKEYO-OWUOR T, Benesh E, Bibbey S, Reid M, et al
    Exposure to maternal obesogenic diet worsens some but not all pre-cancer phenotypes in a murine genetic model of prostate cancer.
    PLoS One. 2017;12:e0175764.
    PubMed     Text format     Abstract available


  84. SCHUBERT C, Waletzko O, Weiss C, Voelzke D, et al
    Intercenter validation of a knowledge based model for automated planning of volumetric modulated arc therapy for prostate cancer. The experience of the German RapidPlan Consortium.
    PLoS One. 2017;12:e0178034.
    PubMed     Text format     Abstract available


  85. TENNILL TA, Gross ME, Frieboes HB
    Automated analysis of co-localized protein expression in histologic sections of prostate cancer.
    PLoS One. 2017;12:e0178362.
    PubMed     Text format     Abstract available


  86. DELOBEL JB, Gnep K, Ospina JD, Beckendorf V, et al
    Nomogram to predict rectal toxicity following prostate cancer radiotherapy.
    PLoS One. 2017;12:e0179845.
    PubMed     Text format     Abstract available


  87. RIVERA M, Ramos Y, Rodriguez-Valentin M, Lopez-Acevedo S, et al
    Targeting multiple pro-apoptotic signaling pathways with curcumin in prostate cancer cells.
    PLoS One. 2017;12:e0179587.
    PubMed     Text format     Abstract available


  88. ZEDAN AH, Blavnsfeldt SG, Hansen TF, Nielsen BS, et al
    Heterogeneity of miRNA expression in localized prostate cancer with clinicopathological correlations.
    PLoS One. 2017;12:e0179113.
    PubMed     Text format     Abstract available


  89. PASHAEI E, Pashaei E, Ahmady M, Ozen M, et al
    Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy.
    PLoS One. 2017;12:e0179543.
    PubMed     Text format     Abstract available


  90. ROY A, Ramalinga M, Kim OJ, Chijioke J, et al
    Multiple roles of RARRES1 in prostate cancer: Autophagy induction and angiogenesis inhibition.
    PLoS One. 2017;12:e0180344.
    PubMed     Text format     Abstract available


  91. POLANEC SH, Andrzejewski P, Baltzer PAT, Helbich TH, et al
    Multiparametric [11C]Acetate positron emission tomography-magnetic resonance imaging in the assessment and staging of prostate cancer.
    PLoS One. 2017;12:e0180790.
    PubMed     Text format     Abstract available


  92. ZHANG Y, Su X, Kong Z, Fu F, et al
    An androgen reduced transcript of LncRNA GAS5 promoted prostate cancer proliferation.
    PLoS One. 2017;12:e0182305.
    PubMed     Text format     Abstract available


  93. ENDT K, Goepfert J, Omlin A, Athanasiou A, et al
    Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer.
    PLoS One. 2017;12:e0181557.
    PubMed     Text format     Abstract available


  94. ZHANG ZH, Xie DD, Xu S, Xia MZ, et al
    Total glucosides of paeony inhibits lipopolysaccharide-induced proliferation, migration and invasion in androgen insensitive prostate cancer cells.
    PLoS One. 2017;12:e0182584.
    PubMed     Text format     Abstract available


  95. WANG K, Jin S, Fan D, Wang M, et al
    Anti-proliferative activities of finasteride in benign prostate epithelial cells require stromal fibroblasts and c-Jun gene.
    PLoS One. 2017;12:e0172233.
    PubMed     Text format     Abstract available


  96. SUMIDA I, Yamaguchi H, Das IJ, Anetai Y, et al
    Robust plan optimization using edge-enhanced intensity for intrafraction organ deformation in prostate intensity-modulated radiation therapy.
    PLoS One. 2017;12:e0173643.
    PubMed     Text format     Abstract available


  97. ZHAN W, Gedroyc W, Xu XY
    The effect of tumour size on drug transport and uptake in 3-D tumour models reconstructed from magnetic resonance images.
    PLoS One. 2017;12:e0172276.
    PubMed     Text format     Abstract available


  98. LI SL, Ye Y, Yuan XH
    Association between Allogeneic or Autologous Blood Transfusion and Survival in Patients after Radical Prostatectomy: A Systematic Review and Meta-Analysis.
    PLoS One. 2017;12:e0171081.
    PubMed     Text format     Abstract available


  99. ZHOU J, Gao S, Hsieh CL, Malla M, et al
    Peptide B targets soluble guanylyl cyclase alpha1 and kills prostate cancer cells.
    PLoS One. 2017;12:e0184088.
    PubMed     Text format     Abstract available


  100. LUCAS JL, Tacheny EA, Ferris A, Galusha M, et al
    Development and validation of a Luminex assay for detection of a predictive biomarker for PROSTVAC-VF therapy.
    PLoS One. 2017;12:e0182739.
    PubMed     Text format     Abstract available


  101. CANESIN G, Evans-Axelsson S, Hellsten R, Krzyzanowska A, et al
    Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model.
    PLoS One. 2017;12:e0184418.
    PubMed     Text format     Abstract available


  102. GUI B, Hsieh CL, Kantoff PW, Kibel AS, et al
    Androgen receptor-mediated downregulation of microRNA-221 and -222 in castration-resistant prostate cancer.
    PLoS One. 2017;12:e0184166.
    PubMed     Text format     Abstract available


  103. READY D, Yagiz K, Amin P, Yildiz Y, et al
    Mapping the STK4/Hippo signaling network in prostate cancer cell.
    PLoS One. 2017;12:e0184590.
    PubMed     Text format     Abstract available



  104. Correction: Evaluation of different mathematical models and different b-value ranges of diffusion-weighted imaging in peripheral zone prostate cancer detection using b-value up to 4500 s/mm2.
    PLoS One. 2017;12:e0184609.
    PubMed     Text format     Abstract available


  105. LIAO JM, Ommerborn MJ, Clark CR
    Association between features of patient-provider discussions and routine prostate-specific antigen testing.
    PLoS One. 2017;12:e0177687.
    PubMed     Text format     Abstract available


  106. KARLSSON J, Gouveia-Figueira S, Alhouayek M, Fowler CJ, et al
    Effects of tumour necrosis factor alpha upon the metabolism of the endocannabinoid anandamide in prostate cancer cells.
    PLoS One. 2017;12:e0185011.
    PubMed     Text format     Abstract available


  107. SOUZA MF, Kuasne H, Barros-Filho MC, Ciliao HL, et al
    Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer.
    PLoS One. 2017;12:e0184094.
    PubMed     Text format     Abstract available


  108. KANG M, Lee KH, Lee HS, Jeong CW, et al
    Concurrent treatment with simvastatin and NF-kappaB inhibitor in human castration-resistant prostate cancer cells exerts synergistic anti-cancer effects via control of the NF-kappaB/LIN28/let-7 miRNA signaling pathway.
    PLoS One. 2017;12:e0184644.
    PubMed     Text format     Abstract available


  109. OPOKU-ACHEAMPONG AB, Henningson JN, Beck AP, Lindshield BL, et al
    5alpha-reductase 1 mRNA levels are positively correlated with TRAMP mouse prostate most severe lesion scores.
    PLoS One. 2017;12:e0175874.
    PubMed     Text format     Abstract available


  110. LUO Q, Egger S, Yu XQ, Smith DP, et al
    Validity of using multiple imputation for "unknown" stage at diagnosis in population-based cancer registry data.
    PLoS One. 2017;12:e0180033.
    PubMed     Text format     Abstract available


  111. LAISECA JE, Ladelfa MF, Cotignola J, Peche LY, et al
    Functional interaction between co-expressed MAGE-A proteins.
    PLoS One. 2017;12:e0178370.
    PubMed     Text format     Abstract available


  112. ZLITNI A, Yin M, Janzen N, Chatterjee S, et al
    Development of prostate specific membrane antigen targeted ultrasound microbubbles using bioorthogonal chemistry.
    PLoS One. 2017;12:e0176958.
    PubMed     Text format     Abstract available


  113. STROMVALL K, Thysell E, Halin Bergstrom S, Bergh A, et al
    Aggressive rat prostate tumors reprogram the benign parts of the prostate and regional lymph nodes prior to metastasis.
    PLoS One. 2017;12:e0176679.
    PubMed     Text format     Abstract available


  114. ZHAO A, Chen F, Ning C, Wu H, et al
    Use of real-time cellular analysis and Plackett-Burman design to develop the serum-free media for PC-3 prostate cancer cells.
    PLoS One. 2017;12:e0185470.
    PubMed     Text format     Abstract available


  115. ROUVIERE O, Dagonneau T, Cros F, Bratan F, et al
    Diagnostic value and relative weight of sequence-specific magnetic resonance features in characterizing clinically significant prostate cancers.
    PLoS One. 2017;12:e0178901.
    PubMed     Text format     Abstract available


  116. REULEN RC, de Vogel S, Zhong W, Zhong Z, et al
    Physical activity and risk of prostate and bladder cancer in China: The South and East China case-control study on prostate and bladder cancer.
    PLoS One. 2017;12:e0178613.
    PubMed     Text format     Abstract available


  117. YU EJ, Hooker E, Johnson DT, Kwak MK, et al
    LZTS2 and PTEN collaboratively regulate ss-catenin in prostatic tumorigenesis.
    PLoS One. 2017;12:e0174357.
    PubMed     Text format     Abstract available


  118. KHAN S, Simpson J, Lynch JC, Turay D, et al
    Racial differences in the expression of inhibitors of apoptosis (IAP) proteins in extracellular vesicles (EV) from prostate cancer patients.
    PLoS One. 2017;12:e0183122.
    PubMed     Text format     Abstract available


  119. ROBLES-FERNANDEZ I, Martinez-Gonzalez LJ, Pascual-Geler M, Cozar JM, et al
    Association between polymorphisms in sex hormones synthesis and metabolism and prostate cancer aggressiveness.
    PLoS One. 2017;12:e0185447.
    PubMed     Text format     Abstract available


  120. MURPHY C, Rettedal E, Lehouritis P, Devoy C, et al
    Intratumoural production of TNFalpha by bacteria mediates cancer therapy.
    PLoS One. 2017;12:e0180034.
    PubMed     Text format     Abstract available


  121. THON A, Teichgraber U, Tennstedt-Schenk C, Hadjidemetriou S, et al
    Computer aided detection in prostate cancer diagnostics: A promising alternative to biopsy? A retrospective study from 104 lesions with histological ground truth.
    PLoS One. 2017;12:e0185995.
    PubMed     Text format     Abstract available


  122. MORLANDO M, Pelullo CP, Di Giuseppe G
    Prostate cancer screening: Knowledge, attitudes and practices in a sample of men in Italy. A survey.
    PLoS One. 2017;12:e0186332.
    PubMed     Text format     Abstract available


  123. LEAPMAN MS, Westphalen AC, Ameli N, Lawrence HJ, et al
    Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa).
    PLoS One. 2017;12:e0185535.
    PubMed     Text format     Abstract available


  124. ARTHURS C, Murtaza BN, Thomson C, Dickens K, et al
    Expression of ribosomal proteins in normal and cancerous human prostate tissue.
    PLoS One. 2017;12:e0186047.
    PubMed     Text format     Abstract available


  125. HEBBRECHT T, Van Audenhove I, Zwaenepoel O, Verhelle A, et al
    VCA nanobodies target N-WASp to reduce invadopodium formation and functioning.
    PLoS One. 2017;12:e0185076.
    PubMed     Text format     Abstract available


  126. AL-MAHROUKI A, Giles A, Hashim A, Kim HC, et al
    Microbubble-based enhancement of radiation effect: Role of cell membrane ceramide metabolism.
    PLoS One. 2017;12:e0181951.
    PubMed     Text format     Abstract available


  127. XIAO WJ, Zhu Y, Dai B, Ye DW, et al
    Evaluation of the major changes in eighth edition of the American Joint Committee on Cancer pathological staging for prostate cancer treated with prostatectomy.
    PLoS One. 2017;12:e0187887.
    PubMed     Text format     Abstract available


  128. TAUROZZI AJ, Beekharry R, Wantoch M, Labarthe MC, et al
    Spontaneous development of Epstein-Barr Virus associated human lymphomas in a prostate cancer xenograft program.
    PLoS One. 2017;12:e0188228.
    PubMed     Text format     Abstract available


  129. JEON HG, Yoo JH, Jeong BC, Seo SI, et al
    Comparative rates of upstaging and upgrading in Caucasian and Korean prostate cancer patients eligible for active surveillance.
    PLoS One. 2017;12:e0186026.
    PubMed     Text format     Abstract available


  130. ANDERSEN S, Richardsen E, Rakaee M, Bertilsson H, et al
    Expression of phosphatase of regenerating liver (PRL)-3, is independently associated with biochemical failure, clinical failure and death in prostate cancer.
    PLoS One. 2017;12:e0189000.
    PubMed     Text format     Abstract available


  131. PASQUIER D, Nickers P, Peiffert D, Maingon P, et al
    Hypofractionated stereotactic boost in intermediate risk prostate carcinoma: Preliminary results of a multicenter phase II trial (CKNO-PRO).
    PLoS One. 2017;12:e0187794.
    PubMed     Text format     Abstract available


  132. ABDEL-RAHMAN O
    Assessment of the prognostic value of the 8th AJCC staging system for patients with clinically staged prostate cancer; A time to sub-classify stage IV?
    PLoS One. 2017;12:e0188450.
    PubMed     Text format     Abstract available


  133. JAMES LJ, Wong G, Craig JC, Hanson CS, et al
    Men's perspectives of prostate cancer screening: A systematic review of qualitative studies.
    PLoS One. 2017;12:e0188258.
    PubMed     Text format     Abstract available


  134. VONDALOVA BLANAROVA O, Safarikova B, Herudkova J, Krkoska M, et al
    Cisplatin or LA-12 enhance killing effects of TRAIL in prostate cancer cells through Bid-dependent stimulation of mitochondrial apoptotic pathway but not caspase-10.
    PLoS One. 2017;12:e0188584.
    PubMed     Text format     Abstract available


  135. STROMVALL K, Lundholm M, Thysell E, Bergh A, et al
    Highly aggressive rat prostate tumors rapidly precondition regional lymph nodes for subsequent metastatic growth.
    PLoS One. 2017;12:e0187086.
    PubMed     Text format     Abstract available


  136. JEDROSZKA D, Orzechowska M, Hamouz R, Gorniak K, et al
    Markers of epithelial-to-mesenchymal transition reflect tumor biology according to patient age and Gleason score in prostate cancer.
    PLoS One. 2017;12:e0188842.
    PubMed     Text format     Abstract available


  137. RICHARDSEN E, Andersen S, Al-Saad S, Rakaee M, et al
    Evaluation of the proliferation marker Ki-67 in a large prostatectomy cohort.
    PLoS One. 2017;12:e0186852.
    PubMed     Text format     Abstract available


  138. KOO K, Brackett CD, Eisenberg EH, Kieffer KA, et al
    Impact of numeracy on understanding of prostate cancer risk reduction in PSA screening.
    PLoS One. 2017;12:e0190357.
    PubMed     Text format     Abstract available


  139. EINELUOTO JT, Jarvinen P, Kenttamies A, Kilpelainen TP, et al
    Repeat multiparametric MRI in prostate cancer patients on active surveillance.
    PLoS One. 2017;12:e0189272.
    PubMed     Text format     Abstract available


  140. DENSLOW A, Switalska M, Jarosz J, Papiernik D, et al
    Clopidogrel in a combined therapy with anticancer drugs-effect on tumor growth, metastasis, and treatment toxicity: Studies in animal models.
    PLoS One. 2017;12:e0188740.
    PubMed     Text format     Abstract available


    January 2016
  141. APRELIKOVA O, Tomlinson CC, Hoenerhoff M, Hixon JA, et al
    Development and Preclinical Application of an Immunocompetent Transplant Model of Basal Breast Cancer with Lung, Liver and Brain Metastases.
    PLoS One. 2016;11:e0155262.
    PubMed     Text format     Abstract available


  142. MASOOMPOUR SM, Lankarani KB, Honarvar B, Tabatabaee SH, et al
    Changing Epidemiology of Common Cancers in Southern Iran, 2007-2010: A Cross Sectional Study.
    PLoS One. 2016;11:e0155669.
    PubMed     Text format     Abstract available


  143. ONER C, Turgut Cosan D, Colak E
    Estrogen and Androgen Hormone Levels Modulate the Expression of PIWI Interacting RNA in Prostate and Breast Cancer.
    PLoS One. 2016;11:e0159044.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: